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Abstract
Background: Single birth cohort studies have been the basis for many discoveries about early life risk factors for
childhood asthma but are limited in scope by sample size and characteristics of the local environment and population.
The Children’s Respiratory and Environmental Workgroup (CREW) was established to integrate multiple established
asthma birth cohorts and to investigate asthma phenotypes and associated causal pathways (endotypes), focusing on
how they are influenced by interactions between genetics, lifestyle, and environmental exposures during the prenatal
period and early childhood.
Methods and results: CREW is funded by the NIH Environmental influences on Child Health Outcomes (ECHO)
program, and consists of 12 individual cohorts and three additional scientific centers. The CREW study population is
diverse in terms of race, ethnicity, geographical distribution, and year of recruitment. We hypothesize that there are
phenotypes in childhood asthma that differ based on clinical characteristics and underlying molecular mechanisms.
Furthermore, we propose that asthma endotypes and their defining biomarkers can be identified based on personal
and early life environmental risk factors. CREW has three phases: 1) to pool and harmonize existing data from each
cohort, 2) to collect new data using standardized procedures, and 3) to enroll new families during the prenatal period
to supplement and enrich extant data and enable unified systems approaches for identifying asthma phenotypes and
endotypes.
Conclusions: The overall goal of CREW program is to develop a better understanding of how early life environmental
exposures and host factors interact to promote the development of specific asthma endotypes.
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Background
The environment during the prenatal period and in early
life is a major contributor to the risk of developing child-
hood asthma. Birth cohort studies from single research
centers have identified individual factors that affect the risk
for developing childhood asthma, including exposure to
allergens, pollutants, bacteria, psychosocial stress, viral
respiratory illnesses and patterns of microbial colonization.
Despite such advances, further progress in understanding
the root causes of asthma have been hampered by the
relatively small size of previous studies that typically lack
diverse population and broad assessments of early life
exposures. Thus, single cohorts lack the resources to inte-
grate multiple types of complex data to identify the individ-
ual and combined effects of environmental factors in
asthma development, asthma phenotypes and endotypes.
Furthermore, broad and diverse populations and environ-
mental assessments are needed to determine and compare
interactions with genetics, effect sizes, mediation and addi-
tive effects and dose response relationships, and to identify
geographical and temporal differences in exposures and
how they impact asthma development across the US. An-
other notable limitation of individual cohorts with modest
sample size is the inability to define prenatal and early life
risk factors for infrequent outcomes that are of special clin-
ical significance, such as severe asthma and susceptibility to
acute exacerbations. Furthermore, differences in data col-
lection and sample analyses make it challenging to pool,
harmonize and integrate findings from different cohorts.
To help overcome these challenges, investigators leading
12 asthma birth cohorts and three additional scientific
centers across the U.S. have established the Children’s Re-
spiratory and Environmental Workgroup (CREW) consor-
tium. Collectively, the CREW consortium will identify
phenotypes of childhood asthma to develop an understand-
ing of which early life environmental influences are causally
associated with these different types of asthma and when
their influences are relevant, and to identify targets for fu-
ture efforts aimed at preventing childhood asthma.
Methods
Study overview
CREW is funded as part of the NIH Environmental Influ-
ences on Child Health Outcomes (ECHO) program [1]. As
such, in addition to pooling data and samples among
CREW cohorts, CREW data also will be shared with the
larger ECHO program. ECHO consists of 34 initial collab-
orative awards to birth cohorts or consortia that are inves-
tigating effects of early life exposures on five health
outcomes in childhood: 1) airway disease (e.g. CREW), 2)
obesity, 3) perinatal outcomes, 4) neurocognitive develop-
ment, and 5) positive health. Enrollment for ECHO is cur-
rently underway and the total study population will include
about 50,000 families, including the new families recruited
during the prenatal period by all ECHO awardees.
CREW consists of 12 individual U.S. birth cohorts and
three scientific centers (Table 1). Each of the cohorts
was originally established with a major focus on identify-
ing prenatal and/or early life exposures that influence
the development of asthma. The initial enrollment for
CREW cohorts included nearly 9000 newborns, and
Table 1 CREW Member Cohorts* and Study Populations
Initial Enrollment Location Population Recruitment Cauc/WH AA Hispanic Asian Other/Missing
CAS 835 Suburban Detroit General 1987–1989 752 (90%) 22 (3%) 20 (2%) 26 (3%) 15 (2%)
CCAAPS 762 Cincinnati High risk 2001–2003 579 (76%) 158 (21%) 0 (0%) 2 (0.3%) 23 (3%)
CCCEH 727 Manhattan and Bronx General 1998–2006 0 291 (40%) 436 (60%) 0 0
COAST 289 Madison High risk, suburban 1998–2000 243 (87%) 12 (4%) 8 (3%) 0 (0%) 7 (2%)
EHAAS 505 Boston High risk 1994–1996 370 (74%) 64 (12%) 30 (6%) 28 (6%) 7 (1%)
IIS 482 Tucson General 1997–2003 280 (58%) 24 (5%) 125 (26%) 0 (0%) 53 (11%)
INSPIRE 1952 Middle Tennessee General 2012–2014 1269 (65%) 351 (18%) 176 (9%) 0 (0%) 156 (8%)
MAAP 120 Metro Detroit General 2014–2016 85 (71%) 22 (18%) 0 (0%) 4 (3%) 9 (8%)
TCRS 1246 Tucson General 1980–1984 822 (66%) 50 (4%) 312 (25%) 0 (0%) 62 (5%)
URECA 609 NYC, St Louis,
Baltimore, Boston
High risk, urban 2004–2006 22 (4%) 429 (70%) 116 (19%) 0 (0%) 42 (7%)
WHEALS 1258 Metro Detroit General 2003–2007 325 (26%) 787 (63%) 81 (6%) 30 (2%) 35 (3%)
WISC 212 Rural WI Rural: farm and
non-farm
2013–2019 204 (96%) 4 (2%) 2 (1%) 2 (1%) 0 (0%)
Total 8997 4951 (55%) 2214 (25%) 1306 (15%) 92 (1%) 409 (4%)
*Abbreviations: CAS, Children’s Asthma Study; CCAAPS, Cincinnati Childhood Allergy and Air Pollution Study; CCCEH, Columbia Center for Children’s Environmental
Health Cohort; COAST, Childhood Origins of Asthma study; EHAAS,; IIS, Infant Immune Study; INSPIRE, Infant Susceptibility to Pulmonary Infections and Asthma
Following RSV Exposure study; MAAP, Microbes, Allergy, Asthma and Pets study; TCRS, Tucson Children’s Respiratory Study; URECA, Urban Environment and
Childhood Asthma study; WHEALS, Wayne County Health Environment Allergy and Asthma Longitudinal Study; WISC, Wisconsin Infant Study Cohort
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approximately 6000 of whom are still being followed.
Study designs with enrollment criteria for the individual
cohorts have been previously described [2–17]. The in-
vestigators of CREW member cohorts have a broad var-
iety of expertise related to early life environmental
exposures, allergy and immunology, mechanisms of
asthma pathogenesis, geospatial technology, pulmonol-
ogy, epidemiology, virology, biostatistics, biomedical in-
formatics, genetics, epigenetics and transcriptomics. In
addition, there are three scientific centers to provide
core services for analyses of the microbiome (University
of California, San Francisco), genetics and epigenetics
(University of Chicago) and geospatial data analyses
(Harvard School of Public Health). The administrative
center for CREW is at the University of Wisconsin-
Madison, and Rho Inc. (Chapel Hill, NC) is the Coordin-
ating Center for CREW.
CREW has three main hypotheses (Fig. 1). First, longi-
tudinal analyses of individual characteristics, including
patterns of respiratory symptoms, aeroallergen-specific IgE,
lung function, sex and ethnicity can be used to identify
respiratory phenotypes, including those that are highly
enriched for asthma. We further propose that these pheno-
types will have closer associations with etiologic factors (e.g.
environmental exposures, genetics), compared to a general
yes/no definition of childhood asthma due to reduction in
misclassification. Second, host factors (e.g. genetics) interact
with environmental exposures during the prenatal period
and early childhood, leading in some cases to epigenetic al-
terations, and ultimately to specific changes in immune and
lung development that increase the risk for specific asthma
endotypes. Finally, molecular biomarkers can be identified
to provide a precise and comprehensive identification of
childhood asthma endotypes.
To address these hypotheses and goals, the CREW con-
sortium has designed three protocols. The first protocol
(Phase I) pools extant data from the 12 cohorts to address
specific hypotheses. Because the studies were designed by
different groups with their own unique objectives, exten-
sive data harmonization will be required. The second
(Phase II) protocol will collect new data on current partic-
ipants from 10 of the cohorts using standardized proce-
dures and questionnaires and will develop standardized
outcomes within CREW (and ECHO). Because most of
the early life specimens for current CREW participants
already have been collected, a third protocol (Phase III, or
“NewCREW”) initiating a new multisite cohort will allow
standardized collection of prenatal and early life envir-
onmental and immunologic samples to measure factors
that could influence or be related to the development
of allergic diseases and asthma.
Phase I: leveraging extant data
Data sharing agreements
For Phase I, each participating institution reviewed and
approved a consortium and data sharing agreement that
enables within-group (including the ECHO data analysis
center) sharing of previously collected data under a waiver
of consent. This agreement was approved by Human Sub-
jects Committees at each of the participating institutions.
Each of the CREW member cohorts has collected data
and samples related to personal and environmental charac-
teristics that could affect allergic diseases and asthma,
which varied to some degree among cohorts. This informa-
tion includes clinical questionnaires and biological
measures that characterized environmental exposures (e.g.
allergens, pollutants and microbes), family and personal
history of allergic diseases, respiratory infections and ill-
nesses, immune development, genomic data, and microbial
colonization.
The individual datasets have been stripped of protected
health information (PHI) as defined by HIPAA, except for
those indirect identifiers permitted in a limited data set,
such as dates of birth, dates of data and sample acquisi-
tion, and town/city, state and zip code. The current Data
Sharing Protocol also allows for sharing of this pooled
limited dataset with the ECHO Data Analysis Center to
enable collaborative research studies with any of the 72
other ECHO cohorts.
Data harmonization and analysis projects
Demographic and other exposure and outcome data
have been and will continue to be compiled by the indi-
vidual cohorts and sent to the University of Wisconsin
(UW). A Publications Committee has been established
to review and approve analysis concepts and resulting
publications. Data harmonization is a critical function
that allows merging data from the 12 cohorts. The
harmonization process requires understanding the ori-
ginal data definitions provided by cohort investigators
and data managers, and mapping them into a common
Fig. 1 CREW conceptual diagram
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CREW definition developed by informaticians. This pro-
cedure is performed by data scientists at UW working
closely with cohort investigators and data managers.
Geospatial approach
Exposures to environmental toxicants and community
characteristics during the prenatal period and early child-
hood have a significant impact on allergic disease and
asthma. CREW investigators have developed distributed
methods to derive environmental exposures and commu-
nity characteristics, including measures of disparities, for
all CREW participants based on residential locations. A
containerized software platform was developed to enable
individual CREW sites to geocode their participants’ birth
record addresses and link these to community characteris-
tics [18]. Census tract-level information regarding race,
ethnicity, education, housing, and other indicators of
disadvantage/advantage was obtained by collaborators at
Harvard Center for Geographic Analysis (Cambridge, MA)
and the University of Arizona using the decennial U.S. cen-
sus in 1980, 1990, 2000, and 2010. These data, combined
with a TIGER/Line address range geocoder, census tract
boundaries, and analysis code were containerized and dis-
tributed to individual CREW sites. Using this software,
each study site can geocode their participants’ birth record
address and link these to census-tract level information for
further analysis.
Phase II: standardized data collection
The CREW Phase II protocol includes standardized mea-
sures of exposure assessments, immunologic studies, lung
function testing and outcome measures. The measure-
ments will be obtained at least once per life stage interval
(1–4 years, 5–7 years, 8–10 years, 11–14 years, 15–17
years and 18 years and over) to standardize measurements
while accommodating different schedules of the cohorts.
Enrollment criteria and recruitment procedures
Participating families from 10 of the CREW member co-
horts are eligible for Phase II study enrollment. Exclusion
criteria include past or current medical problems that
could pose additional risks from participation in the study,
interfere with the participant’s ability to comply with study
requirements or otherwise adversely impact the quality or
interpretation of the data. Recruitment techniques varied
by study site, but study coordinators generally provided in-
formation about CREW and an invitation to participate
during usual cohort activities by phone, email, mail, or at
in-person study visits. For cohorts lacking upcoming activ-
ities, sites used mailings, secure web-based communication
or phone calls to provide information and an invitation to
join CREW. For recruitment of adult participants, sites had
the flexibility to contact them first via mail or email to
gauge interest in participating in CREW. This included a
short questionnaire to assess current allergies and asthma,
and an invitation to join the new study.
Individual site Human Subjects Committees approved
the CREW Phase II protocol. Families or adult partici-
pants provide informed consent and children between
the ages of 7 and 18 years provide assent before being
enrolled in CREW and ECHO.
Questionnaires
Questionnaires will be administered to assess the clinical,
environmental and medication history of the participants
(Table 2). Questionnaire administration will include paper
questionnaires, online questionnaires, electronic case re-
port forms (eCRF), and interviewer-administered ques-
tionnaires. The study’s primary source of information on
the occurrence and frequency of wheezing is the Airways
Outcomes questionnaire. This questionnaire includes
questions from the ISAAC study [19], supplemented by
additional questions related to food allergy, asthma medi-
cation use, anaphylaxis and allergic rhinitis. The Airways
Outcomes questionnaire (Online data supplement) will
also be administered by other ECHO cohorts, to enable
standardized outcome assessments for allergic diseases
and asthma across all ECHO cohorts. Additional ques-
tionnaires will include Tanner staging, parental or self-
assessment of atopic dermatitis (POEM [20, 21]), and
demographic information, among others (Table 3).
Physical examination
Physical examination will include anthropomorphics and
measurement of heart rate and blood pressure.
Blood samples
Peripheral blood will be being collected as fasting morning
samples when possible, especially between ages 8–17 years
to enable measurement of sex hormones, insulin and glu-
cose. Approximately 15 mL will be obtained at each annual
clinic visit. These samples will be transported to the center’s
laboratory on the day of collection and at room
temperature. At the center-specific laboratories, blood will
be processed and aliquots of serum and plasma will be
cryopreserved at − 80 °C. In addition, peripheral blood
mononuclear cells will be separated from heparinized blood
and cryopreserved in aliquots using pre-chilled alcohol res-
ervoirs. A complete blood count and differential will be per-
formed, and plasma will be analyzed for allergen-specific
IgE (Uni-CAP, ThermoFisher). DNA from peripheral blood
samples will be stored for studies of epigenetic regulation.
Airway samples
Nasal wash, blow or lavage specimens will be collected
using techniques that are tailored to the age of the child.
For young children (birth to age 3–4 years), we will col-
lect a nasal wash specimen by instilling 2 ml of buffered
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Table 2 Study Activities in the CREW Standardized Data Collection Protocol*
Age (in years)
1–4 5–7 8–10 11–13 14–17 > 18
Visit window + 12 mon + 12 mon + 12 mon + 12 mon + 12 mon + 12 mon
Time 2.0 h 3.0 h 3.0 h 3.0 h 3.0 h 3.0 h
Essential procedures
Consent/Assent x x x x x x
Eligibility x x x x x x
Distribute home collection kits x x x x x x
PE and anthropomorphics x x x x x x
Questionnaires x x x x x x
Blood x x x x x x
Urine x x x x x x
Stool x x x o x o
Nasal wash/blow/lavage w b l l l l
Home dust collection x
Spirometry x x x
Spirometry w/ reversibility x o o o x
eNO x x x x x
AE collection x x x x x x
Optional procedures
Nasal brushing o o o
Prick skin tests o o o o o o
Phone call (Follow up) x x x x x x
Abbreviations: w, nasal wash; b, nasal blow; l, nasal lavage; o, optional
Table 3 Standardized Questionnaires and Timing of Administration
Age in years
Questionnaire 1–4 5–7 8–10 11–13 14–17 > 18
Demographics
- Addresses x x x x x x
- Household census
- SES
Asthma control
- ACT or Pediatric ACT x x x x x
Self-Tanner Stage x x x
Health history
- Allergic disease and asthma x x x x x x
- Allergic rhinitis
- Atopic dermatitis
- Food allergies
- Perinatal (if not prospectively recorded)
POEM (for atopic dermatitis) x x x x x x
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saline into the nose using a modified bulb syringe,
followed by gentle suctioning is applied to recover the
sample [22]. For capable preschool children, we will use
a nasal blow technique [23]. The procedure involves
wetting the nose with normal saline spray, followed by
blowing the nose into a collection tube.
For adults and children over the age of 8 years, a nasal
lavage will be performed. Following a nasal blow while
in a sitting position, saline is introduced into the one
nostril, and nasal lavage fluid is passively recovered from
the other nostril. This is repeated on the other side.
For each of these nasal samples, separate aliquots will
be prepared for analyses of virology, microbiome, host
cell gene expression, proteins and other analytes.
Nasal epithelial cells will be obtained brushing the infer-
ior turbinate of one nasal passage using a nylon flocked
swab. The epithelial cells will be a source for mRNA and
DNA (epigenetics) isolation.
Other samples (stool, urine, saliva)
The participant will be asked to provide stool samples
to examine fecal bacterial and fungal content. The
sample can be collected during the clinic visit or at
home using the collection kit and directions. If the
specimen is collected at home, it can be mailed to
the laboratory or brought to the clinic on the day of
the study visit. Clean catch urine will be collected for
measurement of chemical exposures, inflammation or
biomarkers that might be related to asthma. Home
collection kits will be distributed during the consent-
ing visit. Pre-packaged collection kits and directions
will be given to the participant and/or parent/guard-
ian for collection of stool and urine. The study staff
will review the directions with the participant and/or
parent guardian.
Allergy skin testing
Prick skin testing to identify aeroallergen sensitization
using a Multi-Test PC device (Lincoln Diagnostics, De-
catur, IL) is an optional procedure at each of the life
stages. Indoor and outdoor allergens that were selected
for local prevalence (Table 4, Greer Laboratories). Wheal
sizes are measured after 15 min. The wheal’s longest
length and width (measured perpendicular to the length
at its midpoint) are measured to the nearest millimeter
and averaged to give a mean wheal size. A positive reac-
tion is defined as a mean wheal size at least 3 mm larger
than the saline control.
Total and allergen-specific IgE
Total and allergen-specific IgE antibodies are measured by
fluoroenzyme immunoassay (ImmunoCAP, ThermoFisher,
Uppsala, Sweden). The panel of specific IgE antibodies
vary by age and in some cases region of the country. For
detection of sensitization in early childhood, the specific
IgE panel includes egg white, milk, peanut and a multiple
aeroallergen screen (Phadiotop, ThermoFisher). If the
Phadiotop is positive, a panel of aeroallergen-specific IgE
(cat, dog, mold mix, and house dust mite mix) is mea-
sured. For adults and children over the age of 5 years,
aeroallergen testing includes birch or oak, ragweed, and
Timothy grass; and Dermatophagoides farinae, Dermato-
phagoides pteronyssinus, dog epithelium, cat dander/epi-
thelium, German cockroach, mouse urine protein, and
Alternaria alternata. Measurement of IgE antibodies to
selected allergens will be performed at each life stage.
Lung function and exhaled nitric oxide (eNO)
To provide standardized protocols for lung function meas-
urement, equipment, and overreading of studies, CREW
has established a Pulmonary Function Core. Equipment
was selected for spirometry (Jaeger Sentry Suite, Mettawa
IL) and measurement of eNO (NIOX VERO®, Circassia
Pharmaceuticals Inc., Morrisville, NC). Computer software
is loaded on spirometers at each site with onsite training
available to facilitate secure transmission of studies to the
central server. CREW coordinators attended a 2-stage
training session for introductory and advanced spirometry.
All lung function studies will be overread by an experienced
respiratory technician in Madison.
Beginning at age 5–7 years, children will perform a
test for measurement of eNO. Prior to spirometry, ex-
haled NO is measured employing a technique modified
after Silkoff et al. [24] and following American Thoracic
Table 4 CREW skin test antigens
Test # Extract
1 Control, 50% (V/V) glycerin
2 Histamine 10 mg/ml
3 Mouse epithelia
4 Dog epithelia
5 Cat hair (standardized)
6 D. farinae + D. pteronyssinus mix
7 American/German cockroach mix
8 Penicillium notatum/Penicillium chrysogenum
9 Alternaria tenuis
10 Cladosporium herbarum
11 Aspergillus mix
12 Ragweed mix (giant and short)
13 Eastern 6 tree mix (American beech, eastern
cottonwood, red oak, red/river birch, shagbark
hickory, white ash)
14 K-O-T grass mix (Kentucky blue/june, orchard,
timothy)
15 Maple/box elder mix
16 3 weed mix (cockleburr, lamb’s quarter, pigweed)
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Society guidelines for eNO assessment [25]. In brief, this
technique utilizes a resistive device that provides a con-
stant low expiratory flow rate and ensures velum closure.
Spirometry will be conducted during clinic visits at each
life stage beginning at 5–7 years according to ATS guide-
lines [26]. Participants will be asked to hold albuterol for 4
h prior to this procedure, and long-acting beta agonists for
12 h before the visit. If the participant feels they need to
take their medication because their symptoms get worse,
they will be instructed to do so and call the study staff.
Reversibility following administration of albuterol (4
puffs) will be performed at ages 5–7 years of age and in
adults (≥ age 18 years) and is optional for intermediate
age groups. After completion of spirometry as described
above, albuterol via MDI with spacer will be adminis-
tered. Fifteen minutes later the spirometry will be re-
peated. In females ≥ age 12 years, urine pregnancy tests
will be conducted to ensure that and this reversibility
test will not be performed in pregnant woman.
Investigator training
Face-to-face and web-based training sessions were held
for sample collection and processing and to review ques-
tionnaires and recruitment procedures. The initial face-to-
face training occurred in December 2017 at the University
of Wisconsin-Madison, and included study coordinator
and lab representatives from each of the clinical centers.
Sessions were designed to cover clinical procedures relat-
ing to collection and processing of biological samples, as
well as pulmonary function testing, exhaled nitric oxide
testing, and consenting. After completion of the in-person
training, we conducted additional web-based training ses-
sions during bi-weekly coordinator calls. These sessions
are recorded for new staff to review in the future for certi-
fication. Web-based training is ongoing and occurs regu-
larly as issues and concerns arise.
CREW employs a comprehensive manual of procedures
that cover all aspects of study management and protocol
implementation. The training program includes a mixed
methodology approach, an accountability component, and
pre-recorded training modules to ensure standardization of
the training process. To assess training effectiveness, skills
are evaluated with written exams, by observation, or certifi-
cation with a qualified trainer, and by on-going quality
control evaluations. Training completion is tracked using a
web application (Moodle, https://moodle.org), which is
monitored regularly by the Coordinating Center.
Phase III: recruitment of additional families
The CREW phase III protocol (“NewCREW”) will enroll
approximately 400 additional pregnant women and their
infants during the prenatal period at four CREW centers.
The purpose of this protocol is to collect early life ex-
posure, biospecimens, and outcomes data for the CREW
and ECHO protocols. There will be an emphasis on col-
lection of maternal specimens during the prenatal period
and extensive pre-, peri- and postnatal environmental
sampling. The sampling strategy was designed to supple-
ment and enrich existing data in CREW and ECHO and
will provide specimens that are optimized for analyses of
early life environmental exposures (e.g. microbial expo-
sures and colonization), immune development (gene
transcription, metabolites and proteins), epigenetics (nasal
cells) and outcomes (e.g. wheeze, growth, allergic
sensitization). Outcomes data will be collected for allergic
diseases and asthma, and other ECHO outcomes including
perinatal outcomes, neurocognitive development, obesity
and positive health.
Collaboration with the ECHO data collection protocol
The primary objective of the ECHO-wide Cohort Data
Collection Protocol is to facilitate the creation of a data
platform consisting of essential data elements from all
participating ECHO awardees, plus recommended data
elements from subsets of cohorts. This protocol stan-
dardizes new data collection across the ECHO Program
and specifies what data elements cohorts should collect
(new data) and share (both existing data and new data)
across the life course, from the prenatal period through
adolescence, to create the ECHO-wide Cohort. CREW is
participating in the ECHO-wide Cohort Data Collection
Protocol in both Phases II and III by collecting essential
and many recommended data elements. This includes
collection of additional biological specimens, such as
hair and toenails, for evaluation of chemical exposures.
Data management
Central database
All 3 phases of CREW will receive support from the CREW
informatics team in data collection, data management, and
the creation of a central database (CREW Asthma eLab)
for the study. Asthma eLab was initially developed by
investigators at the University of Manchester for use in the
STELAR birth cohort consortium [27]. It serves as a secure
database, a forum for investigator interaction, and a
platform for analyses and manuscript development. With
assistance from the NIH, the STELAR group transferred an
updated version of Asthma eLab to the UW-Madison, and
are helping with software customization, installation and
training. STELAR and UW investigators collaborated to
create the state-of-the-art Fast Health Interoperability
Resources (FHIR) profiles needed for the Asthma eLab
platform. These profiles will enable CREW data, research
collaborations, data harmonization and data analyses to
occur within eLab.
Gern et al. Respiratory Research          (2019) 20:115 Page 7 of 14
Data handling and security
We have developed workflows and infrastructure to sup-
port secure data collection for different parts of the CREW
project. Electronic clinical research forms (CRFs) were de-
signed and implemented in REDCap to document consent
for the Phase II CREW protocol, and a dashboard was im-
plemented to track recruitment. Using a similar approach,
about 30 CRFs were implemented to support data collec-
tion for the Phase II protocol. An Information Governance
Policy was written and approved by the CREW Steering
Committee to provide detailed rules for data access, hand-
ling and security.
Quality control
Quality monitoring procedures for new data collection
activities have been established for CREW and start with
comprehensive training and certification of all staff before
performing any study procedures. All CREW study data
are subject to comprehensive built-in edit checks and man-
ual queries as part of the REDCap data entry system. The
CREW Coordinating Center employs a suite of statistical
data checks to examine data for outliers and anomalies.
Standard and custom reports and dashboard visualization
displays (e.g. recruitment status, sample explorer tool) are
used to monitor data quality and study performance and
will be available to all CREW research staff via the CREW
password-protected website (RhoPORTAL). These proce-
dures will be implemented with each of the CREW proto-
cols. In addition, we will implement and adhere to all
quality monitoring procedures that will be established for
the ECHO Data Collection Protocol.
Computation and statistical analyses
The CREW Bioinformatics and Biostatistics Core (BBC)
The BBC was formed to conduct and oversee key computa-
tional and statistical analysis tasks. These include establish-
ing and operating the CREW e-Lab system, as described in
the previous section. Analytic tasks include identification of
the predominant asthma phenotypes and endotypes in the
subject population using the high-dimensional, heteroge-
neous data (symptoms, lung function measures, immuno-
logic variables, etc.). In addition, the BBC will develop
models and statistical approaches to identify relationships
among key variables in the complex data sets, including
measures and load of exposure, epigenetic modifications,
transcriptional profiling, metabolomics, protein expression
and asthma phenotypes. These models will include longitu-
dinal measurements, assessment of age dependency and
consideration of covariates, effect modifiers and mediators.
Because there is a wide range of methodologies that can
be applied to these tasks, and the CREW team encom-
passes a broad range of data-science expertise, we antici-
pate that we will investigate, develop, and evaluate a
variety of approaches for each task. In broad terms, some
of the methodologies we will investigate include unsuper-
vised learning, supervised learning, causal modeling,
spatial modeling, and hypothesis testing. The BBC is com-
prised of biomedical bioinformaticists and statisticians
from each site of our consortium. This team approach has
the advantages of including investigators who are intim-
ately familiar with the data sets while bringing a broad
range of analytic expertise to the group.
Results
Phase I: leveraging extant data
Study population
The study participants of the CREW consortium repre-
sent a diverse national sample of children and their fam-
ilies recruited over the past 30 years into the 12 member
cohorts. The total combined study population is 8997 at
the time of birth (Table 1). The study population is quite
diverse in terms of current age (ages < 1 through 36
years), date of recruitment (1980–2018), race and ethni-
city. There is also considerable variation in the
geographic locations of study participants, with repre-
sentation from the East Coast (Baltimore, Boston, New
York City), Midwest (Cincinnati, Detroit, Madison,
Marshfield), South (Nashville, St. Louis) and West (Tuc-
son). In addition to including large numbers of urban
participants living close to academic medical centers, the
CREW study population also includes suburban (CAS,
COAST, EHAAS, WHEALS, INSPIRE) and rural (IN-
SPIRE, WISC) children. The study designs include those
selected to represent a general population, high risk co-
horts on the basis of parental history of allergies or
asthma, and stratified populations based on pet owner-
ship (MAAP) or residence on a dairy farm (WISC). Col-
lectively, the CREW consortium represents the largest
and most diverse U.S. longitudinal cohort of children
evaluated for asthma (Table 1).
Available data elements
The ECHO Data Analysis Center (Research Triangle
Inc. and Johns Hopkins University) and CREW Bio-
statistics and Bioinformatics Core have surveyed the
CREW member cohorts to identify common data ele-
ments to help direct the development of collaborative
studies, listed by age group in Fig. 2. All cohorts have
collected address information that will be translated
into geocodes to be used to estimate a broad variety
of exposures. During infancy and early childhood,
multiple cohorts collected information on exposures
to diet, allergens, tobacco smoke and pets. Immuno-
logic testing was conducted in 11 cohorts in early life.
Other areas of common data collection included early
life viral respiratory infections (8 cohorts), allergen
exposure (8 cohorts), obesity (8 cohorts), microbial
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exposures and/or colonization (7 cohorts) and psy-
chosocial stress (5 cohorts). All cohorts collected in-
formation on allergic outcomes and asthma.
Geocoding
All 12 study cohorts completed distributive analyses to
link addresses to geocodes. A total of 8978 birth record
addresses were available for participants enrolled in
CREW cohorts and, of these, 98.1% (n = 8810) were geo-
coded with sufficient precision for additional analyses.
The CREW workgroup has also worked closely with the
ECHO Data Analysis Center (Johns Hopkins University
and RTI) to apply our approach to the entire ECHO
consortium to facilitate similar analyses across all
ECHO cohorts.
Future work in CREW will extend these methods to add-
itional spatiotemporally variable physical (e.g. air pollution,
greenspace, temperature) and social exposures. In addition,
we will link the derived environmental exposures and com-
munity characteristics to longitudinal wheeze phenotypes,
asthma, and other childhood respiratory health outcomes
to examine the associations of environmental exposures
and community characteristics with these outcomes.
Inventory of samples available for analysis
An inventory of stored samples (including serum, cells,
DNA) in CREW cohorts has been completed. An ex-
plorer tool has been developed by the CREW Coordinat-
ing Center to enable CREW investigators to interactively
query available samples by sample type, cohort, and age
of child at collection (Fig. 3). This tool will be used to
identify samples that can be used for “omics” analyses,
allergic outcomes (allergen-specific IgE), biomarkers and
exposure assessments. Importantly, this will provide an
excellent resource for identifying sample sets for collab-
orative ECHO analyses.
Analysis projects and publications
One of the main goals of CREW is to identify respiratory
phenotypes based on longitudinal patterns of wheeze and
other variables closely related to asthma such as allergic
sensitization and lung function. Initial phenotyping of
study participants based on longitudinal analysis of pat-
terns of wheezing illnesses through the first decade of life
is in progress. Analysis projects can be proposed by any
CREW investigator, and are then reviewed and approved
by the Publications and Steering Committees. Investiga-
tors from each cohort then have the final decision as to
whether to participate in an analysis proposal. The ten
currently approved analysis projects are listed in Table 5.
Because there is no universally accepted “gold standard”
definition for the diagnosis of asthma in early childhood
and definitions varied by study, we are exploring several
different ways to classify asthma, including parental report
of doctor-diagnosed asthma, and doctor-diagnosed asthma
with either symptoms or controller therapy in the past 12
months, which can work across all our cohorts.
Phase II: standardized data collection
Participants who are currently enrolled or were previously
enrolled in 10 of the CREW cohorts are being invited to
participate in the standardized prospective CREW visits.
The response by study participants has generally been posi-
tive, with < 5% refusals overall and 78% of the recruitment
target being reached. Study visits began in August 2018,
and the schedule of activities is shown in Table 3.
Phase III: NewCREW
The NewCREW phase III protocol that will enroll approxi-
mately 400 additional pregnant women and their infants
during the prenatal period at four CREW centers is being
drafted. Enrollment is scheduled to begin in 2019.
Discussion
The CREW consortium is integrating data from 12 US
birth and infant cohort studies to identify prenatal and early
life environmental factors that modify the risk for develop-
ing allergic diseases and asthma. These cohorts represent a
number of US demographics, with good representation of
white, African American and Hispanic children and their
families. Each cohort has previously identified risk factors
for the development of allergies and asthma and provided
insights into asthma pathogenesis. Pooling data from indi-
vidual cohorts to create the CREW cohort presents further
opportunities, including the ability to test for risk factors
for less common but clinically important outcomes such as
severe childhood asthma, combined effects of multiple risk
factors, geographical differences and mediating effects. Re-
cruitment for some cohorts started in the 1980s while
others are still recruiting today, and the several decade time
span of study participation will enable us to test whether
the risk factors for childhood asthma have changed over
time in concert with marked increases in asthma preva-
lence. Notably, childhood asthma is a syndrome consisting
of multiple asthma phenotypes that are difficult to discern
using cross-sectional observations. By assessing a large
and diverse cohort over time, the ultimate goal of CREW
is to identify phenotypes of asthma and determine
whether there are specific relationships between prenatal
and early life risk factors that contribute to individual
asthma phenotypes.
While this is the first US birth cohort consortium,
several European consortia have been established to
compare study designs and findings, standardize data
collection, and perform meta-analyses or pooled ana-
lyses from multiple individual cohorts [28]. Examples
include the Global Allergy and Asthma European
Network (GA2LEN, established 2004) which brought
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together 25 research institutes in 16 countries to as-
sess exposure variables, and allergic and respiratory
outcome parameters [29]. Several other consortia have
formed since 2009 to combine resources of multiple
cohorts. These include Environmental Health Risks in
European Birth Cohorts (ENRIECO), the Developing
a Child Cohort Research Strategy for Europe (CHI-
COS) consortium, the Mechanisms of the Develop-
ment of ALLergy (MeDALL), and the Study Team for
Early Life Asthma Research (STELAR). CREW repre-
sents a unique opportunity to pool data from US co-
horts. While productivity from individual cohorts has
been high in the US, infrastructures to support col-
laborative research among allergy and asthma birth
cohorts have been lacking. In recognition of this limi-
tation, the NIAID and NHLBI sponsored the Birth
Cohorts in Asthma and Allergic Diseases workshop in
2013 together with investigators from the MeDALL
consortium [30]. This workshop developed strategies
for harmonization of existing asthma birth cohort
data, discussed study designs and standardized
methods for new data collection, and identified areas
of unmet needs. The conference attendees, which in-
cluded many current CREW and ECHO investigators,
concluded that “establishing criteria for asthma phe-
notypes that are mechanistically-based and reflect bio-
logical entities, including degrees of severity, is the
highest priority”. The CREW consortium is designed
Fig. 2 Data elements common to multiple cohorts. The number of cohorts that collected each data element is shown according to maternal
prenatal exposure (a) and childhood life stage (b); infancy 0–11 mo., early childhood 1–4 years, middle childhood 5–11 years, adolescence
12–18 years)
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to address this knowledge gap by pooling existing
data, enriching these data through additional analyses
on stored samples, and by enrolling new families into
a protocol designed to optimize sampling procedures
for systems analysis (genetics and epigenetics, micro-
bial genomics, transcriptomics and metabolomics).
Our goal is to analyze these data sets using predictive
modeling techniques to identify endotypes of asthma
related to specific environmental and personal risk
factors. Pooling of existing data sets within CREW ra-
ther than performing meta-analyses should be helpful
with respect to ease of analysis, greater statistical
power, and availability of advanced statistical tech-
niques that require a single data set.
CREW cohorts have additional opportunities for col-
laborative research within the U.S. and internationally.
As a component of ECHO, standardized questionnaires
and data elements have been developed to measure early
Table 5 Approved CREW analysis proposals
Title Participating Cohorts
CAS CCAAPS CCCEH COAST EHAAS IIS INSPIRE MAAP TCRS URECA WHEALS WISC Total
Childhood research definitions of asthma
outcomes
X X X X X X X X X 9
The natural history of pediatric asthma X X X X X X X X X 9
Role of CDHR3 and 17q21 genetic variants
as determinants of wheezing phenotypes
in early life
X X X X X X X X X X X X 12
Metabolomic profiling to identify pathways
and endotypes of atopic and non-atopic
childhood wheeze
X X X 3
Estimating wheezing severity in young children
using a latent variable approach with the ISAAC
wheezing module*
X X 2
Vertical transmission of vaginal microbiota
to the infant gut
X X 3
Fine mapping of the 17q21 region and asthma X X X X X X X X X 10
Regional and individual level socioeconomic
characteristics of the CREW consortium
X X X X X X X X X X X X 12
RSV and RV respiratory viral wheezing illness
and 17q12–21 genotype
X X X X X 5
*Published [32]
Fig. 3 Samples collected by birth cohorts participating in the CREW consortium. The types of samples are indicated by the row titles, and the
number of cohort-specific samples are color coded
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life exposures that could affect multiple aspects of child
health (perinatal outcomes, neurocognitive development,
obesity and respiratory health). In addition, ECHO in-
cludes an integrated outcome entitled “positive health”,
which incorporates measures of physical, mental and so-
cial wellbeing. Detailed assessment of these outcomes
will enable CREW investigators to test for interactions
among these health conditions and allergies and asthma
in a large sample size (estimated 50,000 participants).
Approximately two thirds of ECHO cohorts have pro-
spectively collected information about respiratory out-
comes, and all will complete standardized allergy and
respiratory outcome assessments. In addition, about a
quarter of the cohorts had focused on asthma prior to
ECHO, and the ECHO Airways Outcome Working Group
has a rich extant data set of predictors and outcome as-
sessments for allergic diseases and asthma. Furthermore,
adaptation and collaborative development of the STELAR
Asthma eLab for use in CREW will promote research
efforts between US and European cohorts.
Limitations of the CREW Consortium are mainly
related to the different study designs and methods used
to collect early life data. As a result, data will need to be
harmonized to enable pooling for group analyses.
Because the majority of the children are school-aged or
older, most of the early life data in CREW already have
been collected. Nonetheless, some opportunities exist
for enriching data sets with the use of retrospective
questionnaires. For example, retrospective analyses of
pet ownership during early childhood correlates well
with prospectively collected data [31]. In addition, use of
time-adjusted geospatial technology will enable enrich-
ment of early life exposure data related to pollutants and
a wide range of social and economic variables.
In conclusion, CREW represents the first large scale
collaborative study involving U.S. birth cohorts focused
on allergic diseases and asthma in children. Pooling of
extant data in CREW and using standardized outcomes
will provide many opportunities to identify early life en-
vironmental exposures that are linked to specific endo-
types of asthma. As part of the ECHO program, CREW
will also have access to data from a much larger sample
size and be able to ask questions about the relationship
between asthma and other health outcomes in children.
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